Sector News

J&J buys Irish stroke care firm in multimillion euro deal

April 11, 2017
Life sciences

Galway medtech company Neuravi has been taken over by US life sciences giant Johnson & Johnson Codman Neuro business in a landmark deal that gives J&J access to the fast-growing strokecare market.

While details of the price paid for the business have not been disclosed, it is understood that the Neuravi deal is the largest exit for a venture-backed medtech in Europe since 2009. That was the $700 million purchase of a company called Corvalve by Medtronic, suggesting that the Neuravi deal is valued comfortably in the hundreds of millions of euro.

That would deliver a significant payday for the company’s founders and early stage investors.

Removing clots
Neuravi’s EmboTrap device captures and removes clots from blood vessels and restores blood flow. Mechanical retrieval of blood clots has become the industry standard over the past two to three years.
Ischemic stroke, caused by clots in vessels supplying blood to the brain, accounts for 87 per cent of all strokes , reportedly affecting one million patients in Europe every year and a further 700,000 in the United States.

Neuravi’s third-generation device has managed to secure around 30 per cent market share against established rivals Medtronic, Stryker and a newer California company Penumbra, since securing regulatory approval in Europe.

It has recently fully enrolled a pivotal US trial which it expects to deliver results later this year.
It is understood that, under the terms of the deal, Neuravi will continue to operate and expand from its Galway base following the acquisition by Corden’s DePuy Ireland subsidiary.

Management team
Neuravi had raised just over €25 million in funding since its foundation by three former executives at another Galway-based medical device business, MedNova, that was acquired in 2005 by Abbott Laboratories.

The company is led by founders Eamon Brady, who is chief executive, chairman John O’Shaughnessy and chief technical officer David Vale. They will stay with the business under its new ownership.

Abbott was an early investor in the business, which also attracted Fountain Healthcare and Delta Partners in a 2012 series A funding round and top European healthcare investor Life Science Partners in the 2015 series B fundraising.

Fountain Healthcare is the largest single investor in the business, which also features the Western Development Commission and Enterprise Ireland among its investors alongside its founders.

“This is a company that has knocked the ball out of the park,” said Justin Lynch, a partner at Fountain Healthcare Partners which was an early investor in the company. “They have beaten every milestone, earlier and with less money that budgeted, which is almost unheard of in this business.”

By Dominic Coyle

Source: Irish Times

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach